 | Sanofi–GSK COVID-19 vaccine (redirect from Vidprevtyn Beta) The Sanofi–GSK COVID-19 vaccine sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK. The Sanofi–GSK COVID‑19... 18 KB (1,385 words) - 20:42, 22 January 2024 |
Archived from the original on 30 December 2021. Retrieved 19 January 2022. "VidPrevtyn Beta". European Medicines Agency (EMA). 4 November 2022. Archived from... 192 KB (21,930 words) - 19:29, 15 April 2024 |
Zealand Turkey The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a subunit vaccine developed by Sanofi Pasteur and GSK plc. It... 318 KB (19,351 words) - 20:33, 14 March 2024 |
| response Pending authorization Sanofi–GSK COVID-19 vaccine (VAT00008, Vidprevtyn) Sanofi Pasteur, GSK France, United Kingdom Subunit (SARS-CoV-2 S adjuvanted... 98 KB (20,593 words) - 02:58, 8 March 2024 |
 | 20 December 2021 21 March 2022 VLA2001 24 June 2022 9 September 2022 VidPrevtyn Beta 10 November 2022 12 December 2022 Bimervax (COVID-19 Vaccine HIPRA)... 52 KB (2,317 words) - 06:53, 15 April 2024 |
Victoza (Novo Nordisk) vidarabine (INN) Vidaza Videx vidofludimus (INN) Vidprevtyn Beta vidupiprant (INN) Viekirax Vienva vigabatrin (INN) Vigadrone Vigamox... 8 KB (451 words) - 02:34, 19 April 2024 |
| old, arriving in Bulgaria in late October 2022. On 10 November 2022, VidPrevtyn Beta received EMA's and the European Commission's authorization, with... 449 KB (34,069 words) - 23:00, 25 December 2023 |